New Jersey resident Moises A. Sanabria recently pleaded guilty to charges of conspiracy to distribute the illicit drugs fentanyl and money laundering. Sanabria, 32, was charged in southern Illinois yesterday, October 25, for his collaboration with an India-based company, according to the United States Department of Justice.
The collaboration between Sanabria and Indian nationals Aashish K. Jain and M. Eshwar Rao is another in a series of incidents showing the expanding reach of illicit pharmaceutical distributions that ignore geographical boundaries. The dangers posed by these networks to public health and safety are considerable, making this case one of high importance.
Between January 2018 and March 2021, court documents reveal, Sanabria received pills containing furanyl fentanyl and tapentadol from an India-based pharmaceutical company in New Jersey and then shipped those pills to customers across the U.S. Illegally distributing these substances, classified under the Controlled Substances Act as Schedule I and II drugs, constitutes a federal crime.
The Department of Justice pointed out, Sanabria's behavior posed a serious threat to public safety. Licensed medical professionals should be the only ones to prescribe these potentially lethal substances to ensure responsible consumption. However, as evidenced by this case, entities and individuals look for ways to bypass the system to distribute such substances illegally.
In recent years, fentanyl, due to its potency and potential to cause fatal overdoses even in small quantities, has emerged as a significant concern for the authorities. This incident reinforces the need for continued vigilance against drug trafficking networks, especially when such potent drugs are involved.
Michael E. Rehg, Acting Assistant Special Agent in Charge and head of DEA Enforcement Operations in southern Illinois, characterized it as deceptive how Sanabria shipped his drug orders from India. Most American consumers may not have been aware of the nature of the products they were ordering or who was supplying them. Rehg further highlighted the money laundering aspect of Sanabria’s operations, where he transferred drug proceeds between the U.S. and India through a New York-based limited liability company.
